#fatty liver disease

Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.

As people with HIV live longer thanks to effective antiretroviral treatment, they are prone to a host of additional health problems.

As with HIV-negative individuals, non-alcoholic fatty liver disease is tied to diabetes and irregular blood lipids in those with HIV.

Fatty liver disease is tied to risk of metabolic problems in people with HIV.

The injectable hormone helps reduce inflammation and fibrosis associated with NAFLD in this population.

Non-alcoholic steatohepatitis, the more severe form of non-alcoholic fatty liver disease, is highly prevalent in the HIV population.

Researchers call for greater use of noninvasive measures of fatty liver disease in this population to identify those at risk.

About a quarter of people taking a higher dose of Ocaliva saw an improvement in liver fibrosis.

The application is based on study results showing that up to 23% of treated patients saw an improvement in liver fibrosis.

Study finds people who took daily aspirin had a lower risk of NASH and advanced liver scarring.

The number of HIV-positive Medicare recipients with liver disease is rising, almost entirely as a result of NAFLD

Non-alcoholic fatty liver disease can lead to more severe, potentially fatal liver diseases, including cirrhosis.

A recent study found that daily cannabis use was associated with a reduced risk of the liver condition in this population.

Among people with HIV who don’t have hepatitis C virus, various factors raise the risk of liver fibrosis and fatty liver disease.

Metabolic disorders are linked to liver scarring and fat accumulation in HIV-positive people.